 | |||||||
| technology | |||||||
| NEWS | |||||||
Retifanlimab Lengthens Survival for Patients With Anal Cancer Adding retifanlimab (Zynyz) to standard carboplatin and paclitaxel chemotherapy significantly extended progression-free survival (PFS) in patients with inoperable locally recurrent or metastatic advanced squamous cell carcinoma of the anal canal (SCAC) ...
| |||||||
| See more results | Edit this alert | |||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment